Navigation Links
WaferGen Announces Data Presentations From Newly Launched High-Throughput SmartChip Human microRNA Panel V2 at Scientific Conferences, Including AACR
Date:3/29/2011

FREMONT, Calif., March 29, 2011 /PRNewswire/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art genomic analysis systems, today announced data presentations from its recently announced industry-leading high-throughput SmartChip Human microRNA Panel V2 at three key scientific conferences.

  • Researchers in the Oncology Division at Stanford University School of Medicine will present data obtained using the SmartChip Human microRNA Panel V2 in a panel of drug-resistant human breast cancer cell lines (Late-Breaking Abstract #351) at the American Association for Cancer Research (AACR) 102nd Annual Meeting 2011, April 2-6, 2011, Orlando, FL;
  • WaferGen's David Ginzinger, Ph.D., VP Genomics Research and Applications, is presenting "Screening 1200 miRNAs with a Single Real-Time PCR Run with the SmartChip System" at the 7th Annual CHI microRNA in Human Disease and Development, March 28-30, Cambridge, MA; and
  • WaferGen is showing data on microRNA gene expression profiling using the SmartChip System at the 5th International qPCR Symposium and Industrial Exhibition and Applications Workshop, March 28, 2011 to April 1, 2011, Freising-Weihenstephan, Technical University of Munich, Physiology-Weihenstephan, Germany.
  • The company will be demonstrating the SmartChip Real-Time PCR System at all three conferences.

  • "These presentations help to corroborate that the SmartChip Human microRNA Panel V2 offers the most comprehensive and up-to-date survey panel on the market," said Alnoor Shivji, chairman and CEO, WaferGen.  "Our SmartChip System continues to gain traction and market share with the world's leading genomics researchers."

    The SmartChip Human microRNA Panel V2 is a component of the company's platform technology, the SmartChip System, which specifically analyzes microRNAs (Ribonucleic Acid).  MicroRNAs affect gene regulation and their expression is associated with a number of diseases.  This more comprehensive panel specifically enables profiling of 1200 human microRNAs on a single chip, not possible on other real-time PCR systems.  It enables discovery, validation and screening of biomarkers in a flexible, high-throughput, highly cost-effective manner.

    Cancer diagnosis, prognosis, and treatment are important potential clinical applications of microRNA profiling.  MicroRNAs are small non-protein-coding single-stranded RNA molecules of 20-24 nucleotides in length that function as negative regulators of gene expression by targeting specific messenger RNAs. This either inhibits translation or promotes messenger RNA degradation.

    About WaferGen and the SmartChip Real-Time PCR SystemWaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for genomic analysis for the life science and pharmaceutical industries.  The company currently offers the breakthrough SmartChip Real-Time PCR System, the next-generation Real-Time PCR system for discovery and validation of biomarkers, or gene expression patterns, on a single platform. WaferGen believes that the SmartChip System is ideal for researchers seeking to confirm discoveries made with the growing use of next-generation sequencing.  In addition, the high throughput capabilities of the SmartChip System enable researchers to extend their research across large panels of genes, and hundreds of samples, at a very reasonable cost.

    Combined with next-generation chemistry and optimized assays being developed by WaferGen under the guidance of David Gelfand, Ph.D., Chief Scientific Officer and one of the pioneers of PCR, the SmartChip System is designed to provide accurate, highly sensitive and high-throughput gene expression profiling capabilities to researchers, clinicians and pharmaceutical companies.

    In addition, the company offers an innovative fee-based service for gene-expression profiling using the SmartChip System.  For additional information, please see http://www.wafergen.com.

    Forward-Looking Statements This press release contains certain "forward-looking statements".  Such statements include statements relating to the expected benefits and advantages of the Version 2 SmartChip microRNA panel, statements relating to the expanded market potential of the SmartChip System as a result of the Version 2 SmartChip Human microRNA Panel, statements relating to the expected benefits and advantages of the SmartChip service for gene-expression research, statements relating to the expected benefits and advantages of the SmartChip technology to other applications, statements relating to the expected throughput levels of the SmartChip Real-Time PCR System, and other statements relating to future events are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.

    Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company.  Actual results may differ materially from the expectations contained in the forward-looking statements.  Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively.  More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2009 and the most recent Form 10-Q.  Investors and security holders are urged to read this document free of charge on the SEC's web site at www.sec.gov.  The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.Contact:WaferGen510-651-4450Don Huffman, CFOdon.huffman@wafergen.comJoyce Strandjoyce.strand@wafergen.com
    '/>"/>

    SOURCE WaferGen Biosystems, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. WaferGen Launches High-Throughput SmartChip Human MicroRNA Panel V2
    2. WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results
    3. WaferGen Appoints Industry Leader Dr. Timothy J. Triche to Board of Directors
    4. WaferGen to Present at 13th Annual BIO CEO and Investor Conference
    5. WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board
    6. WaferGen to Present at OneMedForum San Francisco 2011
    7. WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System
    8. WaferGen Announces $7 Million Capital Raise -- $5 Million Equity Private Placement Agreement Signed, and $2 Million Credit Facility Closed
    9. WaferGen Reports Second Quarter 2010 Financial Results
    10. WaferGen to Introduce New Service for Gene-Expression Profiling Using the SmartChip(TM) Real-Time PCR System
    11. WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/23/2017)... 2017  A new genetic test has been ... individuals who carry HLA-B*15:02 and who ... potentially deadly side effect of certain medications used ... HLA-B*15:02 is strongly associated with life-threatening ... and toxic epidermal necrolysis in patients treated with ...
    (Date:3/23/2017)... March 23, 2017 On ... the trading session at 5,821.64, up 0.48%; the ... finish at 20,661.30; and the S&P 500 closed ... based as six out of nine sectors ended ... initiated reports coverage on the following Medical Instruments ...
    (Date:3/23/2017)... 2017 Pre-market today, Stock-Callers.com has issued ... AGN), Horizon Pharma PLC (NASDAQ: HZNP), and Evoke Pharma Inc. ... part of the Healthcare sector, which was slightly higher in ... the NYSE Health Care Index adding about 0.1% in value, ... also were up nearly 0.1% as a group. Learn more ...
    Breaking Medicine Technology:
    (Date:3/23/2017)... ... 2017 , ... On 2 March 2017, the United States ... Command’s Patriot Award. The award was presented by the USSOCOM Commander, General Raymond ... its significant and enduring support to the command. , Accepting the award ...
    (Date:3/23/2017)... ... March 23, 2017 , ... The Boulevard is honored to host Shriners and ... will be located in the Main West Entrance of The Boulevard (in front of ... appointment is necessary and each child with a parent or guardian will be photographed ...
    (Date:3/23/2017)... ... ... News Advisory/Interview Opportunity , After six years of advocacy, testimony and grassroots organizing, ... health and the environment and is calling on the United States to follow the ... of European citizens, the European Union (EU) will, beginning next year, ban the use ...
    (Date:3/23/2017)... ... ... Woman Be Ye Healed-Passing On A Legacy”: a call to heal the wounded Church. ... author, Desiree M Webb, a registered nurse, minister of music, speaker, songwriter, recording artist, ... husband, Paul, for over twenty-nine years. Desiree enjoys writing, beach trips, ministering in ...
    (Date:3/23/2017)... ... March 23, 2017 , ... Ogden ... innovative patient - centric payment system, to expand its focus on patient care ... patient financial experience. , “At Ogden Clinic, we are working to become ...
    Breaking Medicine News(10 mins):